**Core Concept**
Erythromycin estolate is a prodrug of erythromycin, which is a macrolide antibiotic that can cause cholestatic jaundice due to its hepatotoxic effects. This condition is characterized by the obstruction of bile flow, leading to the accumulation of bilirubin in the blood.

**Why the Correct Answer is Right**
Erythromycin estolate is metabolized in the liver to its active form, erythromycin, which can cause cholestasis by damaging the bile ducts and impairing bile secretion. This results in the accumulation of bile salts and other substances in the blood, leading to jaundice. The exact mechanism of erythromycin estolate-induced cholestasis is not fully understood, but it is thought to involve the formation of toxic metabolites that damage the bile duct epithelium.

**Why Each Wrong Option is Incorrect**
* **Option A:** INH (Isoniazid) is a first-line antituberculosis agent that can cause hepatotoxicity, but it more commonly causes hepatocellular damage rather than cholestatic jaundice.
* **Option C:** Pyrazinamide is another antituberculosis agent that can cause hepatotoxicity, but it is less likely to cause cholestatic jaundice compared to erythromycin estolate.
* **Option D:** Ethionamide is a second-line antituberculosis agent that can cause hepatotoxicity, but it is not as commonly associated with cholestatic jaundice as erythromycin estolate.

**Clinical Pearl / High-Yield Fact**
When prescribing erythromycin estolate, it is essential to monitor patients for signs of cholestatic jaundice, such as dark urine, pale stools, and jaundice. If these symptoms occur, the medication should be discontinued promptly to prevent further liver damage.

**✓ Correct Answer: B. Erythromycin estolate**